Inotersen

Drug Profile

Inotersen

Alternative Names: GSK 2998728; IONIS TTRRx; ISIS 420915; ISIS-GSK1Rx; ISIS-TTRRx

Latest Information Update: 12 Jul 2017

Price : $50

At a glance

  • Originator Isis Pharmaceuticals
  • Developer GlaxoSmithKline; Indiana University School of Medicine; Ionis Pharmaceuticals
  • Class Antisense oligonucleotides
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyloid polyneuropathy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Amyloid polyneuropathy
  • Phase II Amyloidosis; Cardiomyopathies

Most Recent Events

  • 10 Jul 2017 Top-line efficacy data from the phase III NEURO-TTR trial in Amyloid polyneuropathy released by Ionis Pharmaceuticals
  • 15 May 2017 Efficacy and adverse events data from the phase III NEURO-TTR trial in Amyloid polyneuropathy released by Ionis Pharmaceuticals
  • 15 May 2017 Ionis Pharmaceuticals and GlaxoSmithKline complete the phase III trial in Amyloid polyneuropathy in USA, Argentina, Brazil, France, Germany, Italy, New Zealand, Portugal, Spain and United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top